KRAS and Hypomagnesemia: There were five trials of 1723 wild-type KRAS mCRC patients who received either cetuximab- or panitumumab-based chemotherapy, including 568 patients (33.0%) with clinical hypomagnesemia and 1155 patients (67.0%) with normal serum magnesium levels.